Integrated Stress Response and Immune Cell Infiltration in an Ibrutinib-Refractory Mantle Cell Lymphoma Patient Following ONC201 Treatment

被引：0
作者：
Romaguera, Jorge Enrique
Lee, Hun Ju
Tarapore, Rohinton
Prabhu, Varun Vijay
Allen, Joshua E.
Schalop, Lee
Zloza, Andrew
Ok, Chi Young
Badillo, Maria
Wang, Michael
机构：
来源：
BLOOD | 2017年 / 130卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
5163
引用
收藏
页数：2
相关论文
共 50 条
[21]   Ibrutinib Treatment through Nasogastric Tube in a Comatose Patient with Central Nervous System Localization of Mantle Cell Lymphoma [J].
Alsuliman, Tamim ;
Belghoul, Maifa ;
Choufi, Bachra .
CASE REPORTS IN HEMATOLOGY, 2018, 2018
[22]   IBRUTINIB FOR THE TREATMENT OF MANTLE CELL LYMPHOMA (MCL): EVALUATING THE CORRELATION BETWEEN PATIENT-REPORTED OUTCOMES AND DURABILITY OF RESPONSE IN A PHASE 2 STUDY [J].
Rule, S. ;
Goy, A. ;
Martin, P. ;
Ramchandren, R. ;
Alexeeva, J. ;
Popat, R. ;
Avivi, I ;
Advani, R. ;
Le Gouill, S. ;
Horowitz, N. ;
Yuan, Z. ;
Kranenburg, B. ;
Zhuang, S. H. ;
Deraedt, W. ;
Rizo, A. ;
Wildgust, M. ;
Wang, M. .
VALUE IN HEALTH, 2015, 18 (03) :A300-A301
[23]   Ibrutinib for the treatment of relapsed/refractory mantle cell lymphoma: extended 3.5-year follow up from a pooled analysis [J].
Rule, Simon ;
Dreyling, Martin ;
Goy, Andre ;
Hess, Georg ;
Auer, Rebecca ;
Kahl, Brad ;
Hernandez-Rivas, Jose-Angel ;
Qi, Keqin ;
Deshpande, Sanjay ;
Parisi, Lori ;
Wang, Michael .
HAEMATOLOGICA, 2019, 104 (05) :E211-E214
[24]   MATCHING-ADJUSTED INDIRECT COMPARISON OF EFFICACY AND SAFETY OF ACALABRUTINIB VERSUS IBRUTINIB IN THE TREATMENT OF RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA [J].
Telford, C. ;
Kabadi, S. ;
Abhyankar, S. ;
Song, J. ;
Signorovitch, J. ;
Zhao, J. ;
Yao, Z. .
VALUE IN HEALTH, 2019, 22 :S62-S62
[25]   Humoral immune depression following autologous stem cell transplantation is a marker of prolonged response duration in patients with mantle cell lymphoma [J].
Bouard, Louise ;
Tessoulin, Benoit ;
Thieblemont, Catherine ;
Bouabdallah, Kamal ;
Gastinne, Thomas ;
Oberic, Lucie ;
Carras, Sylvain ;
Delette, Caroline ;
Casasnovas, Olivier ;
Dartigeas, Caroline ;
Cacheux, Victoria ;
Masse, Sibylle ;
Hermine, Olivier ;
Le Gouill, Steven .
HAEMATOLOGICA, 2022, 107 (09) :2163-2172
[26]   Median 3.5-Year Follow-up of Ibrutinib Treatment in Patients with Relapsed/Refractory Mantle Cell Lymphoma: A Pooled Analysis [J].
Rule, Simon ;
Dreyling, Martin ;
Goy, Andre ;
Hess, Georg ;
Auer, Rebecca ;
Kahl, Brad S. ;
Hernandez-Rivas, Jose Angel ;
Londhe, Anil ;
Clow, Fong ;
Deshpande, Sanjay ;
Parisi, Lori ;
Wang, Michael .
BLOOD, 2017, 130
[27]   Outcome of East Kent Hospitals University NHS Foundation Trust patients with relapsed/refractory Mantle Cell Lymphoma receiving Ibrutinib treatment [J].
Seviar, D. ;
Young, M. ;
Capomir, M. ;
Lindsay, J. ;
Ratnayake, V. ;
Pocock, C. .
BRITISH JOURNAL OF HAEMATOLOGY, 2018, 181 :181-181
[28]   CAR T cells and time-limited ibrutinib as treatment for relapsed/refractory mantle cell lymphoma: the phase 2 TARMAC study [J].
Minson, Adrian ;
Hamad, Nada ;
Cheah, Chan Y. ;
Tam, Constantine ;
Blombery, Piers ;
Westerman, David ;
Ritchie, David ;
Morgan, Huw ;
Holzwart, Nicholas ;
Lade, Stephen ;
Anderson, Mary Ann ;
Khot, Amit ;
Seymour, John F. ;
Robertson, Molly ;
Caldwell, Imogen ;
Ryland, Georgina ;
Saghebi, Javad ;
Sabahi, Zahra ;
Xie, Jing ;
Koldej, Rachel ;
Dickinson, Michael .
BLOOD, 2024, 143 (08) :673-684
[29]   Dopamine pre-treatment impairs the anti-cancer effect of integrated stress response- and TRAIL pathway-inducing ONC201, ONC206 and ONC212 imipridones in pancreatic, colorectal cancer but not DMG cells [J].
Zhang, Yiqun ;
Tapinos, Nikos ;
Lulla, Rishi ;
El-Deiry, Wafik S. .
AMERICAN JOURNAL OF CANCER RESEARCH, 2024, 14 (05)
[30]   GERMAN PATIENT AND PHYSICIAN PREFERENCES FOR RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA TREATMENT OUTCOMES: A DISCRETE CHOICE EXPERIMENT [J].
Eriksson, J. ;
Landfeldt, E. ;
Ireland, S. ;
Musingarimi, P. ;
Jackson, C. ;
Tweats, E. ;
Gaudig, M. .
HAEMATOLOGICA, 2015, 100 :147-148
12345